Omnicell (OMCL) – Investment Analysts’ Weekly Ratings Updates

A number of research firms have changed their ratings and price targets for Omnicell (NASDAQ: OMCL):

• 8/7/2026 – Omnicell was downgraded by Zacks Research from “hold” to “strong sell”.
• 8/4/2026 – Omnicell had its “hold (c-)” rating reaffirmed by Weiss Ratings.
• 8/3/2026 – Omnicell had its “overweight” rating reaffirmed by Piper Sandler. They now have a $45.00 price target on the stock, down from $55.00.
• 7/31/2026 – Omnicell had its price target lowered by Wells Fargo & Company from $55.00 to $50.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Omnicell had its price target lowered by KeyCorp from $70.00 to $65.00. They now have an “overweight” rating on the stock.
• 7/7/2026 – Omnicell was downgraded by Zacks Research from “strong-buy” to “hold”.

Insider Buying and Selling at Omnicell

In other news, EVP Corey J. Manley sold 5,025 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president owned 112,783 shares of the company’s stock, valued at $4,874,481.26. This represents a 4.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the sale, the executive vice president owned 154,785 shares in the company, valued at approximately $6,689,807.70. The trade was a 1.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is owned by corporate insiders.

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.